REFERENCE
sanofi-aventis.Acomplia(Rm) (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patients. Media Release: 22 Mar 2007. Available from: URL: http://www.sanofi-aventis.com
Rights and permissions
About this article
Cite this article
Sanofi-aventis has announced that its cannabinoid 1 receptor antagonist, Acomplia [rimonabant],. Pharmacoecon. Outcomes News 525, 11 (2007). https://doi.org/10.2165/00151234-200705250-00033
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705250-00033